| 商品名称 | Xagrid |
|---|---|
| 适用类别 | Human |
| 治疗领域 | Thrombocythemia, Essential |
| 通用名/非专利名称 | anagrelide |
| 活性成分 | anagrelide |
| 产品号 | EMEA/H/C/000480 |
| 患者安全信息 | No |
| 许可状态 | Authorised |
| ATC编码 | L01XX35 |
| 是否额外监管 | No |
| 是否仿制药或hybrid药物 | No |
| 是否生物类似药 | No |
| 是否附条件批准 | No |
| 是否特殊情形 | No |
| 是否加速审评 | No |
| 是否罕用药 | No |
| 上市许可日期 | 2004/11/15 |
| 上市许可开发者/申请人/持有人 | Takeda Pharmaceuticals International AG Ireland |
| 人用药物治疗学分组 | Antineoplastic agents |
| 兽用药物治疗学分组 | |
| 欧盟委员会决定日期 | 2023/02/16 |
| 修订号 | 40 |
| 治疗适应症 | Xagrid is indicated for the reduction of elevated platelet counts in at-risk essential-thrombocythaemia (ET) patients who are intolerant to their current therapy or whose elevated platelet counts are not reduced to an acceptable level by their current therapy. An at-risk patient An at-risk ET is defined by one or more of the following features: >60 years of age or; a platelet count >1000 x 109/l or; a history of thrombohaemorrhagic events. |
| 适用物种 | |
| 兽用药物ATC编码 | |
| 首次发布日期 | 2018/07/11 |
| 最后更新日期 | 2023/02/20 |
| 产品说明书 | https://www.ema.europa.eu/en/documents/product-information/xagrid-epar-product-information_en.pdf |
| 公共评估报告 | https://www.ema.europa.eu/en/medicines/human/EPAR/xagrid |